10
Views
34
CrossRef citations to date
0
Altmetric
Cell Growth and Development

p53 Mediates Apoptotic Crisis in Primary Abelson Virus-Transformed Pre-B Cells

, , &
Pages 4825-4831 | Received 22 Dec 1998, Accepted 22 Apr 1999, Published online: 28 Mar 2023
 

Abstract

Transformation of pre-B cells by Abelson murine leukemia virus (Ab-MLV) involves a balance between positive, growth-stimulatory signals from the v-Abl oncoprotein and negative regulatory cues from cellular genes. This phenomenon is reflected by the clonal selection that occurs during Ab-MLV-mediated transformation in vivo and in vitro. About 50% of all Ab-MLV-transformed pre-B cells express mutant forms of p53 as they emerge from this process, suggesting that this protein may play an important role in the transformation process. Consistent with this idea, expression of p19Arf, a protein whose function depends on the presence of a functional p53, is required for the apoptotic crisis that characterizes primary Ab-MLV transformants. To test the role of p53 in pre-B-cell transformation directly, we examined the response of Trp53−/− mice to Ab-MLV. The absence of p53 shortens the latency of Abelson disease induction but does not affect the frequency of cells susceptible to Ab-MLV-induced transformation. However, primary transformants derived from the null animals bypass the apoptotic crisis that characterizes the transition from primary transformant to fully malignant cell line. These effects do not require p21Cip-1, a major downstream target of p53; however, consistent with a role of p19Arf, transformants expressing mutant p53 and abundant p19 retain wild-type p19 sequences.

ACKNOWLEDGMENTS

We thank Philip Leder, Ronald DePinho, and Andrew Beavis for providing reagents critical to this work; Henry Wortis and Allen Parmelee for assistance with flow cytometry; Zohar Sachs for assistance with mice; and Anne Halgren for technical support.

This work was supported by grant CA33771 from the National Institutes of Health.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.